{"entity":{"id":"bcl-xl-inhibitor-payloads","kind":"term","name":"BCL-XL inhibitor payloads","aka":["clezutoclax","mirzotamab clezutoclax","ABBV-155"],"tldr":"These payloads release a brake that can stop damaged cells from dying. Attaching the drug to an antibody aims to concentrate that effect in cancer cells.","summary":"BCL-XL is an anti-apoptotic protein. Primary preclinical research tested BCL-XL inhibitor conjugates and showed that drug-linker changes altered cardiovascular, kidney and platelet toxicities in animal studies. The resulting linker-payload was incorporated into the B7-H3-directed mirzotamab clezutoclax, or ABBV-155. The original solid-tumor trial is completed in the registry. This represents an apoptosis-directed payload, not proof that antibody targeting removes all toxicity from BCL-XL inhibition.","asOf":"2026-11-08","links":[{"label":"Judd et al., BCL-XL inhibitor conjugates (2024)","url":"https://doi.org/10.1126/sciadv.ado7120"},{"label":"ClinicalTrials.gov: NCT03595059","url":"https://clinicaltrials.gov/study/NCT03595059"}],"tags":[],"related":["mcl1-inhibitor-payloads"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/bcl-xl-inhibitor-payloads/","neighbours":{"term":[{"id":"mcl1-inhibitor-payloads","kind":"term","name":"MCL-1 inhibitor payloads","route":"/terms/mcl1-inhibitor-payloads/"},{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}]}}